.40 by Oct to Nov is just simply too low. AMBS man

.40 by Oct to Nov is just simply too low. AMBS management and new hires did not come on board to get to .40. Plus, LPC would likely be expecting at least a 5-10x return beyond their average current accumulation price. Let's say that is .10, so 7x is .70. That's conservative in my opinion. Microcaps might get in before then to help get it there, but the larger funds is when LPC will sell their initial investment. The larger funds will enter upon reverse split and LPC can easily sell into that larger volume. So, in my opinion, Lympro gets this stock to at least .50-.60, and that is bare minimum compared to the estimates I have made in the past. That does not include grants, FDA designations, other partnerships, surprises etc. LPC is basically directing this ship right now so the share price gets to where it needs to be so they can cash in. That is the ONLY way AMBS gets the $20M financing deal they received from LPC. Companies like LPC don't just give financing out that says 'here is $20M line of credit, buy shares at whatever price you want." The catch is they make tons of money off what they are buying now and that is good for all of us.